Lenalidomide Sandoz

Lenalidomide, the active ingredient in Lenalidomide Sandoz, is an immunomodulatory drug (IMiD) presented as an oral formulation for oral use. It is indicated for the treatment of multiple myeloma and myelodysplastic syndromes with del(5q) chromosome abnormality, where it exerts anti‑angiogenic and immune‑enhancing effects.

GNH USA supplies Lenalidomide Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Lenalidomide Sandoz belongs to the immunomodulatory class and is used in hematologic malignancies. - Multiple myeloma: improves progression‑free and overall survival in patients with relapsed or refractory disease. - Myelodysplastic syndromes with del(5q): reduces transfusion dependence and can lead to cytogenetic remission.

Lenalidomide may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Neutropenia: reduced neutrophil count increasing infection risk. - Thrombocytopenia: low platelet levels that may cause bleeding. - Anemia: decreased red blood cells leading to fatigue. - Fatigue: general feeling of tiredness. - Nausea: upset stomach and possible vomiting. - Diarrhea: loose stools.

Serious or Rare Side Effects: - Venous thromboembolism: deep vein thrombosis or pulmonary embolism. - Severe neutropenia: heightened susceptibility to serious infections. - Secondary primary malignancies: emergence of new cancers. - Tumor lysis syndrome: rapid tumor cell breakdown causing metabolic disturbances. - Hypersensitivity reactions: rash, fever, or anaphylaxis.

Before initiating therapy, clinicians should assess patient‑specific risk factors and monitor laboratory parameters. - Monitor blood counts: perform regular CBC to detect cytopenias. - Assess thromboembolic risk: consider prophylactic anticoagulation in high‑risk patients. - Avoid in pregnancy: teratogenic potential requires strict contraception. - Adjust in renal impairment: dose modifications may be needed based on creatinine clearance. - Counsel on contraception: both male and female patients must use effective methods. - Store at room temperature below 25°C: keep in the original packaging, protect from moisture and light.

Lenalidomide can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase lenalidomide exposure. - Strong CYP3A4 inducers (e.g., rifampin): may reduce therapeutic levels. - Anticoagulants (e.g., warfarin): heightened risk of bleeding or altered INR.

Moderate Interactions (Monitor Closely): - P-glycoprotein substrates (e.g., digoxin): potential for increased plasma concentrations. - Immunosuppressants (e.g., cyclosporine): may enhance hematologic toxicity.